Meeting
2023 ASCO Annual Meeting
SARC041: A phase 3 randomized double-blind study of abemaciclib versus placebo in patients with advanced dedifferentiated liposarcoma.
Authors
Mark Andrew Dickson
Memorial Sloan Kettering Cancer Center, New York, NY
Mark Andrew Dickson , Karla V. Ballman , Mia C. Weiss , Steven Attia , Michael J Wagner , Seth Pollack , Edwin Choy , Andrew J. Wagner , Breelyn A. Wilky , Lara E. Davis , Richard F. Riedel , William D. Tap
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Sarcoma
Track
Sarcoma
Sub Track
Soft Tissue Tumors
Clinical Trial Registration Number
NCT04967521
Citation
J Clin Oncol 41, 2023 (suppl 16; abstr TPS11587)
DOI
10.1200/JCO.2023.41.16_suppl.TPS11587
Abstract #
TPS11587
Poster Bd #
517a
Abstract Disclosures
Similar Posters
Poster
2019 ASCO Annual Meeting
A double-blind placebo-controlled randomized phase II trial assessing the activity and safety of regorafenib (REG) in patients (pts) with nonadipocytic soft tissue sarcoma (STS) previously treated with pazopanib (PAZ).
First Author: Nicolas Penel
Poster
2021 ASCO Annual Meeting
A randomized phase II trial of second-line treatment for advanced soft tissue sarcoma comparing trabectedin, eribulin and pazopanib (2ND-STEP, JCOG1802).
First Author: Makoto Endo
Poster
2021 ASCO Annual Meeting
Updated results of European Organization for Research and Treatment of Cancer (EORTC) phase 2 trial 1202 cabazitaxel in patients with metastatic or inoperable locally advanced dedifferentiated liposarcoma.
First Author: Roberta Sanfilippo
Poster
2013 ASCO Annual Meeting
Results of the randomized phase III trial of trabectedin (T) versus doxorubicin-based chemotherapy (DXCT) as first-line therapy in patients (pts) with translocation-related sarcoma (TRS).
First Author: Andrew Eugene Hendifar